Matches in Wikidata for { <http://www.wikidata.org/entity/Q96228372> ?p ?o ?g. }
- Q96228372 description "2020 nî lūn-bûn" @default.
- Q96228372 description "2020年の論文" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年学术文章" @default.
- Q96228372 description "2020年學術文章" @default.
- Q96228372 description "2020年學術文章" @default.
- Q96228372 description "2020年學術文章" @default.
- Q96228372 description "2020年學術文章" @default.
- Q96228372 description "2020年學術文章" @default.
- Q96228372 description "2020년 논문" @default.
- Q96228372 description "article científic" @default.
- Q96228372 description "article scientific" @default.
- Q96228372 description "article scientifique" @default.
- Q96228372 description "articol științific" @default.
- Q96228372 description "articolo scientifico" @default.
- Q96228372 description "artigo científico" @default.
- Q96228372 description "artigo científico" @default.
- Q96228372 description "artigo científico" @default.
- Q96228372 description "artikel ilmiah" @default.
- Q96228372 description "artikull shkencor" @default.
- Q96228372 description "artikulong pang-agham" @default.
- Q96228372 description "artykuł naukowy" @default.
- Q96228372 description "artículo científico publicado en 2020" @default.
- Q96228372 description "artículu científicu" @default.
- Q96228372 description "bilimsel makale" @default.
- Q96228372 description "bài báo khoa học" @default.
- Q96228372 description "naučni članak" @default.
- Q96228372 description "scienca artikolo" @default.
- Q96228372 description "scientific article published on 08 June 2020" @default.
- Q96228372 description "scientific article published on 8 June 2020" @default.
- Q96228372 description "scientific article published on 8 June 2020" @default.
- Q96228372 description "teaduslik artikkel" @default.
- Q96228372 description "tieteellinen artikkeli" @default.
- Q96228372 description "tudományos cikk" @default.
- Q96228372 description "vedecký článok" @default.
- Q96228372 description "vetenskaplig artikel" @default.
- Q96228372 description "videnskabelig artikel udgivet 8. juni 2020" @default.
- Q96228372 description "vitenskapelig artikkel" @default.
- Q96228372 description "vitskapeleg artikkel" @default.
- Q96228372 description "vědecký článek" @default.
- Q96228372 description "wetenschappelijk artikel" @default.
- Q96228372 description "wissenschaftlicher Artikel" @default.
- Q96228372 description "επιστημονικό άρθρο" @default.
- Q96228372 description "мақолаи илмӣ" @default.
- Q96228372 description "наукова стаття, опублікована в червні 2020" @default.
- Q96228372 description "научна статия" @default.
- Q96228372 description "научная статья" @default.
- Q96228372 description "научни чланак" @default.
- Q96228372 description "научни чланак" @default.
- Q96228372 description "מאמר מדעי" @default.
- Q96228372 description "مقالة علمية نشرت في 8 يونيو 2020" @default.
- Q96228372 description "৮ জুন ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q96228372 description "บทความทางวิทยาศาสตร์" @default.
- Q96228372 description "სამეცნიერო სტატია" @default.
- Q96228372 name "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 name "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 type Item @default.
- Q96228372 label "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 label "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 prefLabel "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 prefLabel "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized cont" @default.
- Q96228372 P1433 Q96228372-BCA9CDDF-D29F-45F9-836C-E10BAA0FBC65 @default.
- Q96228372 P1476 Q96228372-1655C044-1586-4B4E-B796-958EA9EA2E1C @default.
- Q96228372 P2093 Q96228372-06719DF0-DB8A-4370-884E-4A7DD5191CDF @default.
- Q96228372 P2093 Q96228372-23289C31-7567-463C-B861-AE7D1848B562 @default.
- Q96228372 P2093 Q96228372-27EFACB5-9A1F-4FE0-850D-B367775B60D2 @default.
- Q96228372 P2093 Q96228372-27F1D68D-D019-4034-8268-3AE08DF153E4 @default.
- Q96228372 P2093 Q96228372-2E735147-A3D2-401A-96AD-3C24C1BD5D0D @default.
- Q96228372 P2093 Q96228372-3F4DFE1B-C4EC-439C-99A1-FE37D15F701C @default.
- Q96228372 P2093 Q96228372-56BB13B9-8DE2-4FA6-9D94-A23A1F83EA54 @default.
- Q96228372 P2093 Q96228372-57BCCFD3-8488-4788-AAA1-74B5BDBBF585 @default.
- Q96228372 P2093 Q96228372-60EDBDC9-6FF0-4DE5-9AD6-50040570EADA @default.
- Q96228372 P2093 Q96228372-662623E6-FB03-46B6-8B94-25C562101CF0 @default.
- Q96228372 P2093 Q96228372-69FD10D2-52CD-41F7-9BFE-A691516E8515 @default.
- Q96228372 P2093 Q96228372-A1C21405-B471-45D2-A529-EC503B3C093C @default.
- Q96228372 P2093 Q96228372-B32994C9-A957-41E5-BC2F-C72345CFF3B1 @default.
- Q96228372 P2093 Q96228372-C65D19CD-E7B3-478C-A329-125BC78DCF2C @default.
- Q96228372 P2093 Q96228372-E216A94B-811F-465E-B4B6-88342E72D58F @default.
- Q96228372 P304 Q96228372-947FCD43-B121-45BE-8AA9-DAC3CF6F92AE @default.
- Q96228372 P31 Q96228372-1975ABB0-7578-4B1E-B733-B4ACA5ABA2E2 @default.
- Q96228372 P356 Q96228372-7D95D3CC-E07D-42F6-8D0B-34A4AC01F735 @default.
- Q96228372 P433 Q96228372-F5C186D5-8308-453A-AB1E-9A684E56FC94 @default.
- Q96228372 P478 Q96228372-AA26C3F9-CCC6-404E-B01D-A5D4B887FB4C @default.
- Q96228372 P50 Q96228372-1FD491B1-E0E2-4000-A029-8D08D9CBEBCD @default.
- Q96228372 P50 Q96228372-29E8EE56-8384-47C2-B378-62D5D3D17ED3 @default.
- Q96228372 P50 Q96228372-51327E5C-9F33-4278-A78C-2D81F4F6B61D @default.
- Q96228372 P50 Q96228372-7D97FE74-2E2B-45FD-B19D-501AAE0F2456 @default.
- Q96228372 P577 Q96228372-49329EBD-4BB2-49A9-A923-7619C0C8F7AA @default.
- Q96228372 P698 Q96228372-39638BE9-E278-4643-9FEE-7C247DBB081F @default.
- Q96228372 P921 Q96228372-22427899-2B02-4078-8728-22A905240AD5 @default.
- Q96228372 P921 Q96228372-4B3FEA2D-533A-4A68-BAEE-0728B4EF96B2 @default.
- Q96228372 P921 Q96228372-EEA974B4-3B80-47B3-950B-C0F054916320 @default.
- Q96228372 P356 S13063-020-04408-W @default.
- Q96228372 P698 32513251 @default.
- Q96228372 P1433 Q7840023 @default.
- Q96228372 P1476 "Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)" @default.